Interleukin-6 (IL-6) is a pleiotropic cytokine that has been postulated as playing a role in the pathogenesis of multiple myeloma, chronic autoimmune diseases, and alcoholic liver cirrhosis. We generated transgenic mice carrying a fusion between the mouse metallothionein-l (MT-I) gene promoter and the human IL-6 cDNA. MT-I/IL-6 transgenics express IL-6 constitutively in the liver and secrete the cytokine in the blood. They show initially activation of acute-phase response genes and accumulation of a2-and p-globulins in the plasma, which is followed by polyclonal hypergammaglobulinemia. MT-I/IL-6 transgenics die between 12 to 20 weeks of age. Histologic examination of transgenic animals at different ages and after necropsy showed, as expected from previous studies of IL-6 disregulation in vivo, an in-I
NTERLEUKIN-6 (L-6) plays a central role as a differentiation and growth factor of hematopoietic precursors, B cells, T cells,'.* keratinocytes, neuronal cells, osteoclasts, and endothelial cells3 In addition, IL-6 modulates the transcription rate of several liver-specific genes during acute inflamm a t i~n .~.~ IL-6 disregulation has been postulated as being responsible for the development of myelomdplasmacytoma,' mesangial glomerulonephritis,8 osteoporosis: cancer cachexia," and various autoimmune diseases such as rheumatoid arthritis.' Also, the high IL-6 levels found in the serum of patients with alcoholic cirrhosis" have created the basis for the theory that IL-6 contributes to the development of this disease.
Mouse models have been used extensively during the last few years to assess a direct cause-effect relationship between overexpression of a given cytokine and the development of pathologic conditions." This same approach has been used with IL-6. Transgenic mice EpAL-6, which overexpress human IL-6 in B cells, develop a polyclonal plasmacytosis with infiltration of plasma cells in the liver, spleen, kidney, and lymph nodes.I3 Interestingly, the polyclonal plasmacytosis switches to transplantable monoclonal plasmacytomas when the IL-6 transgene is introduced into a Balb/C genetic background.I4 Polyclonal plasmacytosis with concomitant hypergammaglobulinemia has also been observed in mice infected with an IL-6-expressing N2 retroviru~.'~ On the contrary, a myeloproliferative disease with no associated plasma-cell proliferation develops in mice infected with murine stem cell virus MSCVIIL-6 carrying the IL-6 gene.I6 Transgenic mice that overexpress IL-6 specifically in the skin develop a thicker stratum corneum, suggesting that IL-6 plays a role in the keratinization of epithelia and protection from injuries and infection^.'^ Hence, it is clear that distinct pathologies are generated by targeting IL-6 overexpression to different body compartments and cell types.
Given the relevance of IL-6 in the acute-phase response and the prevalent distribution of the specific IL-6 receptor in the hepatic tissue (Sugita et all8 and G. Ciliberto, unpublished data), we decided to analyze the consequences of long-term expression of IL-6 in the liver. Transgenic mice were generated that carry the human IL-6 (hIL-6) cDNA under the control of the mouse metallothionein-I (MT-I) promoter." MT-IAL-6 transgenics show a chronic increase of acute-phase gene expression in the liver and of a2-and pglobulins in the plasma, with no macroscopic or microscopic alteration of the liver tissue and IgG plasmacytosis restricted to lymphoid organs. Interestingly, these animals develop a progressive kidney pathology that has no equivalent in previous models of IL-6 disregulation in vivo. Kidney damage, linked to protein leakage and deposition, is ultimately responsible for early death at 12 to 20 weeks of age. Alterations of kidney functions are time-related, with significant and sequential histopathologic lesions both of glomeruli and tubuli. In the final stage, kidney histopathology is dominated by tubuli swelling and occlusion, a picture identical to that observed in patients with multiple myeloma. [PCTI) were determined with the automatic analyzer Cell-Dyn 800 (Sequoia, Santa Clara, CA).
To determine the serum protein profile, 40 pL of serum was subjected to agarose electrophoresis. Strips were stained with Coomassie and the densitometric profile was determined.
Serum and urine Igs were detected by radial immunodiffusion (Binding Site Ltd. Birmingham, UK). One hundred microliters of a 1 : 1 , OOO sera dilution and undiluted urine samples were used.
Determination of urinary proteins. Urinary proteins were measured by Combufiest RL (Boehringer, Mannheim, Germany).
Histopathology. Organs were fixed for more than 16 hours in 3.7% formaldehyde diluted in 50 mmoVL sodium phosphate buffer, pH 7.2, and then included in paraffin. Sections of 5 pm were subjected to hematoxilin-eosin staining.
Statistical analysis. Comparison of means was performed by the Student's t-test. 
RESULTS

Generation of MT-I/)IILd transgenic mice.
TO drive expression of human L -6 in the liver of transgenic mice, we used the promoter of the mouse MT-I gene." The construct (described in Materials and Methods and shown in Fig 1) containing the fusion gene was gel-purified as a Pvu 11-Pvu I1 fragment and microinjected into the pronuclei of fertilized eggs from a cross F1 (C57B16 X DBAII). Four MT-I/IL-6 transgenic founders were obtained. Two died at 5 and 8 weeks of age. A third one (no. 19) was sterile and was killed at 5 months of age at the first signs of illness. Histologic analysis of its tissues showed signs of IL-6-related pathology identical to those of the mice of line 28 (see below).
Only mouse 28 produced a low percentage of positive offspring (10%). Mice of line 28 die between 2 to 5 months of age, with the majority dying at 4 months (approximately 75%) ( Fig 2) . The onset of the disease is characterized by loss of weight and hunched posture; mice die suddenly after 3 to 4 days. hIL-6 expression. Northern blots were performed with RNA from different tissues of mouse 19 and of F1 mice of line 28. IL-6 was expressed constitutively only in the liver of mouse 19 (data not shown) and in mice of line 28 (Fig  3) . A weaker signal was detected in the heart at a slightly lower molecular weight (Fig 3) . Parallel to this result, bioactive hIL-6 was detectable in the blood at a concentration of about l U/pL in mouse 19 and at a concentration 0.15 to 13 U/pL in mice of line 28 (Table 1) . Interestingly, in the latter mice, IL-6 activity (tested in the 7TD1 proliferation assay) increased exponentially after 2 months of age (Table 1 ). This increase was not caused by activation of endogenous mouse IL-6 synthesis, because all bioactive IL-6 in the sera could be inhibited by a specific neutralizing antibody to human IL-63' ( Table 1 ). The increase in hIL-6 blood levels with age is not caused by a progressive increase in the production of the cytokine because we could never detect the appearence of hIL-6 mRNA in organs other than the liver, or increased hIL-6 mRNA levels in the liver tissue with aging (not shown). The most likely explanation, therefore, is that the IL-6 half-life is increased either by complexation in the plasma with carrier proteins such as ~r2-macroglobulin,~~ whose plasma levels are increased, or by impairment of kidney functions caused by kidney damage (see below).
MT-ILL-6 transgenic mice show chronic activation of acute-phase genes. To analyze acute-phase gene activation by IL-6 in transgenic mice, we performed Northern blots with RNA samples using several probes (Fig 4) .
RNA levels for the positive acute-phase reactants hemopexin (HPX), a2-macroglobulin (a2M), al-acid glycoprotein (AGP), and serum amyloid protein ( S A P ) are greatly hIL-6 -mRNA increased, as well as those for transcription factors CEBP/@ and CEBP/S, which are known to be involved in the IL-6 signal transduction pathway and to control the expression of several acute-phase response genes.33'3h On the contrary, mRNA for transcription factor C/EBPa does not undergo any change in MT-I/hIL-6 transgenics and has been used as normalization standard in our Northern blots. In addition, mRNA levels for albumin, which is known to be negatively regulated during acute-phase response. were slightly decreased (Fig 4) .
Biochemical m d hemcrtologic altercctions. The plasma protein profile of MT-I/IL-6 mice was monitored through electrophoretic fractionation on agarose gels ( Fig 5) . An increase of a2-and @-globulins is already detectable in young animals, a direct consequence of acute-phase protein gene induction in the liver. In fact, a2-and &globulin peaks comprise well-known acute-phase reactants such as a 2 M , haptoglobin (a2-globulins). complement C.?, and HPX (8globulins). In contrast, the increase in the al-globulin fraction is not very pronounced, despite the high mRNA levels for AGP, a prominent al-globulin produced by the liver. In IO-week-old transgenics, the alteration of a2-and @-fractions is accompanied by a lesser increase in the y-globulin fraction. The most striking change in the levels of this latter fraction occurs at a later time, on average between IO and 12 weeks. This increase becomes eminent in clinically sick animals in which y-globulins represent about 40% of the circulating plasma proteins. The y-globulin peak is mainly caused by polyclonal IgGl production, as tested by radial immunodiffusion (Fig 6) . The determination of hematologic parameters is summarized in Table 2 . Transgenic animals at terminal stages develop neutrophilia and expansion of the volume of the platelets in the blood. In this case. although the number of PLT undergoes a slight and not significant increase. the MPV and PCT are both significantly higher than in nontransgenic littermates. The high level of neutrophilia is observed only in the last 3 to 4 days before death. and is not caused by a myeloproliferative disease. as has been shown in MSCV/IL-&infected mice, but is probably consequential to kidney damage (see below). The increase of MPV can be attributed to a direct thrornbopoietic activity of IL-6. which is also testified to by the higher number of megakaryocytes observed in the spleen and bone marrow (see below). The direct determination of enzymatic values in the serum (LDH. alkaline phosphatase, and transaminases) did not show any alteration (data not shown). therefore confirming that liver function was not compromised.
Pla.stnacytosis i s restricted only to lynphoid org(rt1.s it1 MT-ML-6 transgenic mice. A characteristic feature of previous models of IL-6 transgenics is the occurrence of polyclonal invasive plasmacytosis. The occurence of IgG hypergammaglobulinemia in MT-I/IL-6 transgenics immediately suggested that a similar pathologic process was also developing in this case and would lead to death caused by massive plasma cell infiltration of the liver, kidney. heart, and lungs. To clarify this point, several animals were killed at different ages. both during the healthy period and after the onset of the disease, and their organs were analyzed. Before the onset of the disease, we detected only a progressive enlargement of the spleen, mostly of its longitudinal diameter. Other macroscopic alterations could be observed only in sick animals. which showed whitening of the kidneys and enlargement of the lymph nodes. Finally. autoptic analysis showed increased volume and clear signs of edema of the lungs.
Histologic examination of the organs and tissues at different ages showed signs of sequential and progressive pathology. In young animals, there was a detectable change in the spleen in which the picture was dominated by an elevated number of giant cells with polymorphic nuclei that could be identified as megakaryocytes ( Fig 7A) . The increase in megakaryocyte number is approximately threefold.
In older animals. we observed a progressive alteration of the structure of lymphoid organs. particularly the spleen and lymph nodes. In both cases there is a gradual invasion by a 
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homogeneous population of compactly arranged plasmocytoid cells characterized by an eccentrically situated nucleus and a basophilic cytoplasm (compare Fig 7B [spleen] and C [peribronchial lymph node]). In cases of advanced disease, this homogeneous population totally subverts the architecture of the spleen. MT-IAL-6 transgenics never showed major alterations in the bone marrow except for the presence of increased megakaryocytes (2-fold; data not shown). Interestingly, the same histopathologic findings, ie, an increase in splenic megakaryocytes and plasmacytosis of lymphoid organs, were also observed in founder mouse no. 19 (data not shown).
This plasmacytosis is similar, both in morphology and arrangement of the cells, to what has been previously observed in EpAL-6 mice.'' However, surprisingly, we never observed infiltration of plasma cells in other organs such as the liver, kidney, lungs, and heart. We could conclude, therefore, that the plasmacytosis itself is not directly responsible for early death of MT-IAL-6 transgenics.
MT-[/[L-6 transgenics develop a specijc kidney pathology.
Examination of transgenic kidneys at different ages and postmortem showed progressive and constant alterations that, in their final stage, testify to loss of kidney function and are responsible for the death of the animal (Fig 8) . uli increases and some of them show signs of glomerulosclerosis. This picture is often accompanied by the presence of protein casts in the tubuli ( Fig 8C) . In dead animals, the totality of the glomeruli is sclerotic and the enlargement of the tubuli is more accentuated, with deposition of proteinaceous material and tubular atrophy ( Fig 8D) . This is in large part caused by the precipitation of circulating Igs produced by the expanded plasma cell compartment, as indicated by direct immunostaining of kidney sections with polyclonal antimouse IgG antibodies (data not shown). This picture closely resembles that observed in patients affected by multiple myeloma. Loss of kidney function is likely to be responsible for the edema in the lungs observed during the autopsy of dead animals (Fig 9) . We never observed signs of plasma cell invasion of either kidneys or lungs. Again, the same two aspects of advanced glomerulosclerosis and tubuli swelling with deposition of proteinaceous material were also observed by histology of kidneys of founder mouse no. 19 (data not shown).
To establish correlations between histopathologic findings, the development of renal insufficiency, and changes in the plasma protein profile, we examined some parameters of kidney function, such as proteinuria and blood urea nitrogen (BUN). The results are shown in Table 3 . Young animals with initial thickening of the mesangial matrix show neither Table 2 ' P < .001.
. Hematologic Parameters in 3-Month-Old fUlT-l/hlL-6 Transgenic Mice
increased BUN nor proteinuria; however, transgenics with overt signs of disease (focal glomerulosclerosis) show proteinuria, mainly caused by IgGI ( Fig IO) . Moreover, in the same animals, a strong increase in BUN could be detected.
DISCUSSION
IL-6 gene disregulation in mice has been shown to cause various forms of pathologies of the immune and hematopoietic systems that are always fatal to the animal.'"'' To explore the pathologic consequences of IL-6 disregulation in the liver tissue, which is one of the main targets of IL-6 activity," we generated transgenic mice carrying the human IL-6 cDNA under the control of the mouse MT-I promoter. Interestingly, although these mice show all the features of acute-phase response during their entire life span, they never develop morphologic and enzymatic alterations of liver functions.
In MT-VIL-6 transgenic mice, acute-phase response is probably caused by the establishment of an autocrine/paracrine stimulatory loop. An IL-6 autocrine loop in in vitro cultures of human hepatoma cells HepG2 leads to the loss of responsiveness to lL-6.3x HepG2-IL-6 cells become refractory to IL-6 and lose acute-phase response, probably as a consequence of the downregulation of the specific surface receptor. Relief from this state can only be achieved by adding sufficient amounts of soluble IL-6 receptor to the cell medium,3x which is known to act as a potentiator of IL-6 activity." This is clearly not the case in MT-IfiL-6 transgenics, and it is thus possible to conclude that, in vivo, the liver tissue does not undergo desensitization to continuous IL-6 stimulation. This difference might be caused by differences between receptor turnover in hepatocytes and in hepatoma cells or by the presence of natural soluble IL-6 receptor in the mouse serum?o More experiments will be needed to clarify this issue.
At the age of IO to 12 weeks, MT-I/IL-6 transgenics develop an IgG plasmacytosis similar to that described for Ed IL6 transgenic mice" and for NUmIL-6 mice." However, there is an important difference. In MT-IfiL-6 mice, the plasmacytosis involves only lymphoid tissues, mainly lymph nodes and spleen. Proliferating plasma cells are never detected in the blood or in other organs, such as the liver, kidney, and lungs; therefore, plasmacytosis is not by itself responsible for death. Furthermore, the increased levels of L -6 in circulation, although responsible for the expansion of the B-cell compartment, are not sufficient to cause the myeloproliferative " "changes similar to those found in MSCV/IL-6-infected mice.'" The only myeloproliferative modification found in MT-VIL-6 mice is an increase in the number of megakaryocytes in the bone marrow and spleen and a significant increase in MPV and PCT. This finding was expected on the basis of the well-known activity of IL-6 as a thrombopoietic factor." However, neither alterations in the bone marrow nor in the bone structure could be detected, thus suggesting that possible myeloproliferative c h a n g e~'~ or disregulation of bone metabo1ism"'can only occur when IL-6 overproduction takes place in the microenvironment of the bone or, in the latter case, is accompanied by estrogen deficiency.
The most interesting and distinctive feature of MT-VIL-6 mice is kidney damage; in fact, kidney failure is responsible for death. However, it must be stressed that we never observed mesangioproliferative glomerulonephritis. This pa- thology has been reported in other cases of !L-6 disregulation'3-IS and has been attributed to a direct effect of IL-6 on mesangial cells. In young MT-I/hfL-6 mice, the first alteration is a general thickening of the interstitial matrix of the glomeruli. This lesion (membranous glomerulonephritis)," concomitant ( Fig 8B) to kidney overload by acute-phase proteins produced by the liver, is still compatible with a normal kidney function because no proteinuria is detectable in these animals. At later stages, we observed focal glomerulosclerosis and tubuli swelling as a consequence of massive deposition of protein casts. Casts are homogeneous, eosinophilic, and often accompanied by tubular atrophy. This picture is surprisingly similar to what, in human pathology, is found in patients at advanced stages of multiple myeloma known as myeloma kidney?' Interestingly, we never detected signs of interstitial nephritis, a common manifestation of myeloma kidney.
Myeloma kidney is believed to be caused by massive precipitation of circulating Igs and/or the Bence-Jones protein. It is important to note that myeloma kidney in MT-I/ IL-6 transgenics develops in the presence of increased polyclonal hypergammaglobulinemia. as opposed to the monoclonal hypergammaglobulinemia that characterizes human myeloma patients. However, more importantly, the same type of kidney damage is not found in Ep/IL-6 transgenics and in N2/mIL-6 mice," which have the same degree of polyclonal hypergammaglobulinemia. but apparently no acute-phase response. We therefore postulate that myeloma kidney might be the resultant of the concomitant development of sustained hypergammaglobulinemia and acute-phase response. In fact, myeloma patients show increased acutephase response markers such as CRP and complement C3 in response to increased levels of circulating IL-6.Jz Hence, it is possible that kidney cells cannot withstand the simultaneous overload of a2-, p-. and y-globulins, or that a specific acute-phase protein induced by IL-6 inhibits y-globulin resorption by tubular cells. Several studies have invoked IL-6 disregulation as the major pathogenetic event in the development of proliferative B-cell abnormalities. which are at the basis of multiple This aspect has been investigated with success using various models of !L-6 disregulation in vivo.'."'' However, it is important to stress that only in the transgenic mice presented in this study was B- For personal use only. on August 30, 2017. by guest www.bloodjournal.org From cell deregulation accompanied by the most common complication of multiple myeloma in humans, ie, kidney failure?'
Although we have been able to establish only a single line (no. 28) carrying the MT-I/hIL-6 transgene, we believe that the phenotype is not a consequence of the disruption of an endogenous gene. First, previous results from studies of IL-6 overexpression are consistent with much of the transgenic phenotype. Second, we generated three other founder mice. Of these, two died within a few weeks of birth, indicating that the MT-IihIL-6 transgene is highly deleterious; the third survived longer and was analyzed at the first signs of illness, showing the same type of pathology as did the mice of line 28. Third, no malformation is evident in kidneys of transgenics at birth and the type of alterations that develop are temporally and biochemically connected, in a direct cause-effect relationship, with the acute-phase response and the hypergammaglobulinemia.
MT-VIL-6 mice thus represent a further contribution to understanding the role of IL-6 in physiologic and pathologic conditions, and constitute a unique model of progressive kidney damage that can be further studied to analyze changes in the function of kidney cells and the beneficial effects of IL-6 antagonists.
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